AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
CUPERTINO, CA, April 12, 2018 -- Aemetis, Inc. (NASDAQ: AMTX) today announced that Universal Biofuels, the company’s India subsidiary, is producing glycerin at above nameplate capacity and demand for the product exceeds supply. The production capacity of the refined glycerin unit at the Kakinada plant is approximately 18,000 metric tonnes per year. The sale of glycerin is an important part of the company’s business strategy in India.
“Our glycerin refining facility in India is operating above nameplate capacity by importing crude glycerin from Argentina and other biodiesel production countries,” stated Eric McAfee, Chairman and CEO of Aemetis. “As our plant scales up biodiesel production using the new pre-treatment unit, the refined glycerin production unit has grown to be an important source of consistent revenues and contribution margins supplying the production of consumer and paint products in India.”
About Aemetis
Headquartered in Cupertino, California, Aemetis is an advanced renewable fuels and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products by the conversion of ethanol and biodiesel plants into advanced biorefineries. Founded in 2006, Aemetis owns and operates a 60 million gallon per year ethanol production facility in California’s Central Valley, near Modesto. Aemetis also owns and operates a 50 million gallon per year renewable chemical and advanced fuel production facility on the East Coast of India producing high quality distilled biodiesel and refined glycerin for customers in India, the US and Europe. Aemetis operates a research and development laboratory, and holds a portfolio of patents and related technology licenses for the production of renewable fuels and biochemicals. For additional information about Aemetis, please visit www.aemetis.com.
External Investor Relations Contact: Kirin Smith PCG Advisory Group (646) 863-6519 [email protected] Company Investor Relations/ Media Contact: Todd Waltz (408) 213-0940 [email protected]
